Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...
Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback